Biocytogen Establishes Sub-brand RenBiologics, A Fully Human Antibody Molecule And Antibody Discovery Platform To Accelerate Global New Drug Research And Development

BEIJING, China--( BUSINESS WIRE )-- ( BUSINESS WIRE )-- Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. ("Biocytogen", stock code: 02315.HK) today Announced the establishment of a sub-brand, RenBiologics™, which covers the licensing and cooperative development of the company's antibody molecules, as well as the licensing of RenMice® fully human antibody/TCR discovery platform ^. The brand logo is designed with a humanoid antibody pattern, which highlights Biocytogen's advantages in the field of fully human antibodies and expresses the company's commitment to jointly developing new antibody drugs with global partners and striving to achieve its vision of becoming the birthplace of global new drugs.

Biocytogen, the antibody molecule licensing and cooperative development business, launched a large-scale antibody development project in March 2020 based on the company's proprietary target knockout RenMice platform - the "Thousand Mice and Ten Thousand Antibodies™" project. In the third quarter of 2023, the "Thousands of Mouse and Ten Thousand Antibodies" project achieved important milestones, with a total of more than 900 targeted fully human antibody development projects completed (more than 40 of which are in the PCC to IND stages), and a total of 400,000-50 Tens of thousands of fully human antibody sequences are available off the shelf. These antibody molecules can be directly provided to global pharmaceutical companies and biotechnology companies for evaluation and licensing cooperation.

At present, Biocytogen's antibody molecule library covers many fields such as tumors, inflammatory and autoimmune diseases, infectious diseases, metabolic diseases, cardiovascular diseases, neurological diseases, etc. Target types include not only traditional cell membrane surface proteins and extracellular secreted proteins, but also some intracellular targets, most of which have not yet been marketed. Antibody molecules obtained through different technology platforms and screening methods are suitable for development into different forms of pharmaceuticals, including monoclonal antibodies, dual/multiple antibodies and cell adapters, dual-antibody ADCs, nanobodies, TCR-like antibodies and cell therapy, etc. . Most of the antibody molecules in the antibody library can be cross-identified across species, which facilitates direct effectiveness and safety analysis in different species.

Biocytogen's high-quality and complete antibody molecule library has been recognized by many of the world's leading biotechnology and biopharmaceutical companies. So far, it has established different patent drug forms such as ADC, dual-antibody ADC, and TCR-like antibodies with companies including many MNCs, such as Merck kGaA, Neurocrine, Ona Therapeutics, Radiance, ADC Therapeutics, Hansoh Pharma, FineImmune, and Remegen. Licensing cooperation on related molecules in oncology and non-oncology fields. In addition, four of the five molecules in the clinical stage have established clinical development licensing cooperation with Chipscreen NewWay Biosciences, TRACON and Syncromune.

RenMice fully human antibody/TCR discovery platform licensing business
Biocytogen can provide RenMice fully human antibody/TCR discovery platform licensing or other flexible business cooperation models. Biocytogen uses proprietary SUPCE technology to establish the RenMice series of fully human antibody/TCR mouse platforms, including RenMab ^® , RenLite ^® , RenNano ^® , RenTCR™ and RenTCR-mimic™ platforms, which are respectively used for fully human monoclonal antibodies and dual Discovery of anti/dual anti-ADCs, nanobodies, TCRs and TCR-like antibodies. After immunization, these mice can produce robust immune responses and generate fully human antibodies with good specificity, high affinity, and good diversity. The key technologies of the RenMab platform have obtained Chinese and American patents, and other technology platforms have also submitted patent applications. Biocytogen has reached licensing agreements with a number of the world's leading biotechnology and biopharmaceutical companies for its RenMice discovery platform, including Merck KGaA, Janssen, Xencor, BeiGene, Innovent, Junshi Biosciences, Remegen, etc.

In the future, Biocytogen will work with partners to accelerate the entry of licensed/cooperated molecules into clinical trials; at the same time, we will further improve the library of thousands of anti-antibody molecules and develop antibody molecules targeting more targets with drug potential, as well as best-in-class antibody molecules. Characteristic antibody molecules to meet the needs of more pharmaceutical companies for the development of innovative drugs. In addition, the company will continue to focus on technological innovation, develop more types of fully human antibody/TCR discovery platforms, and enrich partners’ R&D product line portfolios for different drug forms and target types.

About Biocytogen
Biocytogen (stock code: 02315.HK) is an international biotechnology company that drives the research and development of new drugs through innovative technology, and is committed to becoming the birthplace of new drugs in the world. Based on underlying gene editing technology, Biocytogen independently developed the RenMice ^® ​​(RenMab ^® , RenLite ^® , RenNano ^® , RenTCR-mimic™) platform for fully human therapeutic monoclonal antibodies, bi/multispecific antibodies, Discovery of double anti-ADCs, nanobodies and TCR-like antibodies. Biocytogen is conducting large-scale drug development for more than 1,000 potentially druggable targets ("Thousands of Mouse, Ten Thousand Antibodies™" project), and has established a library of more than 400,000 fully human antibody sequences for global collaboration. As of June 30, 2023, Biocytogen has signed 50 drug cooperative development/authorization/transfer agreements and reached 42 target project RenMice ® ​​platform authorized development cooperation with companies including multiple MNCs ^; multiple Clinical stage antibody molecules have also reached external licensing cooperation. The company's sub-brand BioMice® ^provides thousands of gene-edited animal and cell models, including target humanized mice, and also provides preclinical pharmacology and gene editing services to customers around the world. Biocytogen is headquartered in Beijing and has branches in China (Haimen, Jiangsu, Shanghai), the United States (Boston, San Francisco) and Heidelberg, Germany. For more information, please visit the official website https://www.biocytogen.com.cn/ .

Disclaimer: The original version of this announcement is the officially authorized version. The translation is for convenience of understanding only. Please refer to the original text. The original version is the only legally binding version.

Contacts

RenBiologics consultation: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn